Disclosed is crystalline R(+) -N-propargyl-1-aminoindan and racemic N-propargyl-1-aminoindan characterized by colorless crystals a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is pure liquid R (+) -N-propargyl-1- aminoindan and a pharmaceutical composition comprising the same, and the process for the manufacture thereof.
